Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Meningococcal vaccine is used to prevent diseases caused due to Neisseria meningitidis, also known as meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia.

The global meningococcal vaccines market is estimated to account for US$ 3,341.9 Mn in terms of value and is expected to reach US$ 7,732.3 Mn by the end of 2027.

Global Meningococcal Vaccines Market: Drivers

Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal vaccines market over the forecast period. For instance, according to World Economic Forum’s, 2018 report, 37.4 million tourist arrivals were recorded in Sub-Saharan Africa in 2017.

Moreover, recommendation of various regulatory bodies for meningococcal vaccination is also expected to aid in growth of the market. For instance, the Centers for Disease Control and Prevention recommends meningococcal vaccines for preteens, teens, and certain other people.

North America held dominant position in the global meningococcal vaccines market in 2019, accounting for 36.8% share in terms of value, followed by Asia Pacific and Europe respectively.

Figure 1. Global Meningococcal Vaccines Market Share (%), by Value, by Region, 2019

          Meningococcal Vaccines  | Coherent Market Insights

Global Meningococcal Vaccines Market: Restraints

Significant variations in the incidences and epidemiology of meningococcal disease have been observed both geographically and over time. Thus, broad coverage targeting as many serogroups as possible is needed. The risk associated with travelers is unpredictable making it more difficult to provide evidence-based vaccine recommendations. Such scenario is expected to hinder growth of the market.

Moreover, meningococcal vaccination is optional in several countries, which is also expected to limit the market growth.  

Global Meningococcal Vaccines Market: Opportunities 

Development of vaccines that do not depend on very narrow range temperatures for storage is expected to offer lucrative growth opportunities for players in the market. Till date, there is only one meningococcal vaccine- MenAfriVac that has been approved for use outside the cold chain.

Development of vaccines through collaborations and public private partnerships is also expected to aid in market growth. The innovative MenAfriVac meningococcal vaccine was developed through collaboration between the PATH-WHO Meningitis Vaccine Project, an Indian vaccine manufacturer Serum Institute of India Ltd., and public health officials in India and several African countries. The development was aimed at providing an effective, long-term, and affordable solution to epidemics caused due to meningococcal disease in the African meningitis belt. Such initiatives are expected to aid in development of affordable meningococcal vaccines.

The global meningococcal vaccines market was valued at US$ 2,965.9 Mn in 2019 and is forecast to reach a value of US$ 7,732.3 Mn by 2027 at a CAGR of 12.7% between 2020 and 2027.

Figure 2. Global Meningococcal Vaccines Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Meningococcal Vaccines  | Coherent Market Insights

Market Trends/Key Takeaways

In Europe, there is low meningococcal vaccination coverage among children up to five years old and there is also knowledge gaps about invasive meningococcal disease. For instance, according to the study, ‘Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0–5 years Old Polish Children,’ published in International Journal of Environmental Research and Public Health, in January 2019, only 18.8% of parents self-assessed their knowledge regarding invasive meningococcal disease as good. Knowledge regarding the disease was higher among parents with higher educational level.

Moreover, awareness regarding meningococcal b vaccine among pediatricians in Italy was found to be low. For instance, according to the study, ‘Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy’, published in December 2018, only 28.0% knew the vaccination schedule for meningococcal B serogroup for children aged two years or under.

Regulations

U.S.

The approval of any vaccine in the U.S. is an extensive process that requires submission of a Biologics License Application (BLA) by the vaccine manufacturer.

The FDA medical and scientific staff then executes a detailed assessment of data supporting the safety and effectiveness of the vaccine, and quality of the manufacturing process.

Global Meningococcal Vaccines Market: Competitive Landscape

Major players operating in the global meningococcal vaccines market include, Baxter International, Inc., Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International AG., Pfizer, Inc., Sanofi SA, and Serum Institute of India Ltd.

Global Meningococcal Vaccines Market: Key Developments

Major players in the market are focused on approval and launch of new vaccines to expand their product portfolio. For instance, in April 2020, The U.S. Food and Drug Administration (FDA) granted a Biologics License Application for Sanofi’s MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older.

Major players in the market are also focused on expanding their production capacity. For instance, in September 2019, Serum Institute of India Pvt. Ltd. started a new plant in Pune, India.

Meningitis is an inflammation in the inner lining of the brain and spinal cord that results from infectious (viral, bacterial, and rarely fungal) or non-infectious (drugs, sarcoidosis etc.) factors. The swelling associated with meninges triggers symptoms such as painful headaches, fever, loss of appetite, and stiffness of the neck. Meningitis is a fatal disease and has a rapid onset of action. Meningitis can cause severe damage to the brain in almost half of the total infected population, if untreated. It can also lead to serious ailments such as mental retardation, epilepsy, and deafness. According to Meningitis Research Foundation, as of 2017, around 80% - 90% of meningitis cases are estimated to be caused by enteroviruses and the remaining 10% is estimated to be caused by herpes virus, mumps, measles, and human immune deficiency virus.

Restraints of the Global Meningococcal Vaccines Market

High cost of meningococcal vaccination and low coverage of the same are expected to hinder growth of the global meningococcal vaccines market.

Key features of the study:

  • This report provides in-depth analysis of the global meningococcal vaccines market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global meningococcal vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Baxter International, Inc., Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International AG., Pfizer, Inc., Sanofi SA, and Serum Institute of India Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global meningococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Meningococcal Vaccines Market, By Vaccine Type:
    • Polysaccharide
    • Conjugate
    • Combination
  • Global Meningococcal Vaccines Market, By Distribution Channel:
    • Government
    • Private
  • Global Meningococcal Vaccines Market, By Geography:
    • North America
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Vaccine Type
        • Polysaccharide
        • Conjugate
        • Combination
      • By Distribution Channel
        • Government
        • Private
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Baxter International, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Biomed Pvt. Ltd.
    • GlaxoSmithKline plc
    • JN-International Medical Corporation
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
    • Pipeline Analysis
  4. Global Meningococcal Vaccines Market, By Vaccine Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Polysaccharide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Conjugate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • Combination
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Meningococcal Vaccines Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Government
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Private
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  6. Global Meningococcal Vaccines Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Baxter International, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biomed Pvt. Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • JN-International Medical Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Serum Institute of India Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 24 figures on “Meningococcal Vaccines Market – Global forecast to 2027.

Frequently Asked Questions

The global meningococcal vaccines market was valued at US$ 2,965.9 Mn in 2019 and is forecast to reach a value of US$ 7,732.3 Mn by 2027 at a CAGR of 12.7% between 2020 and 2027.
Major factor driving the growth of global meningococcal vaccines market during the forecast period is increasing prevalence of meningitis, and increasing government initiatives for increasing vaccinations.
Conjugate meningococcal vaccines held dominant position in the global meningococcal vaccines market.
Major factors hampering the growth of the meningococcal vaccines market during the forecast period constitutes of low vaccination coverage in developing economies, and high costs of meningococcal vaccines.
North America meningococcal vaccines market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Baxter International, Inc., Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International AG., Pfizer, Inc., Sanofi SA, and Serum Institute of India Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner